Christian Waage

Average Profitability
<0.0001%
Insider Buys Quantity
5
Insider Buys Sum
$231,062.02
Insider Sells Quantity
7
Insider Sells Sum
$184,997.38

Insider Activity of Christian Waage

According to the SEC Form 4 filings, Christian Waage, being in a position of

  1. EVP, Tech Ops and Admin at Gossamer Bio, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 6430 shares for $7,430,
    over all time since 2019-02-12, has bought 17034 shares for $180,539, and sold 22642 shares for $155,067.

The largest purchase of all time was on 2019-05-15 and amounted to 2800 shares of Heron Therapeutics, Inc. for $50,523.

The largest sale of all time was on 2022-03-23 and amounted to 10722 shares of Gossamer Bio, Inc. for $95,587.

Biography of Christian Waage

No biography is available at this moment.

2024-03-27SaleGossamer Bio, Inc.
GOSS
EVP, Tech Ops and Admin
6,430
0.0028%
$1.16$7,430-24.97%
2022-07-15PurchaseGossamer Bio, Inc.
GOSS
EVP, Tech Ops and Admin
6,934
0.0049%
$7.21$49,994-79.92%
2022-03-23SaleGossamer Bio, Inc.
GOSS
EVP, Tech Ops and Admin
10,722
0.0143%
$8.91$95,587-4.09%
2021-12-21SaleHeron Therapeutics, Inc.
HRTX
director
300
0.0003%
$9.73$2,920-56.73%
2021-09-21SaleHeron Therapeutics, Inc.
HRTX
director
600
0.0006%
$12.31$7,384-54.08%
2021-06-21SaleHeron Therapeutics, Inc.
HRTX
director
600
0.0006%
$15.20$9,118-40.1%
2021-04-15SaleHeron Therapeutics, Inc.
HRTX
director
600
0.0006%
$17.51$10,508-38.97%
2021-03-23SaleGossamer Bio, Inc.
GOSS
EVP & General Counsel
5,490
0.0077%
$9.48$52,051+1.54%
2020-10-14PurchaseGossamer Bio, Inc.
GOSS
EVP & General Counsel
5,000
0.0075%
$9.53$47,636-1.07%
2019-09-27PurchaseGossamer Bio, Inc.
GOSS
EVP & General Counsel
2,000
0.0032%
$16.65$33,308-20.65%
2019-05-15PurchaseHeron Therapeutics, Inc.
HRTX
director
2,800
0.0035%
$18.04$50,523+1.43%
2019-02-12PurchaseGossamer Bio, Inc.
GOSS
EVP & General Counsel
3,100
0.0074%
$16.00$49,600+6.27%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.